This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging.
There is significant racial disparity in prostate cancer (PCa) in terms of incidence, treatment, and outcomes. Racial diversity and compliance with FDA race reporting guidelines in PCa drug registration trials are unknown.
Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage and the leading cause of death in prostate cancer patients, among which bone metastasis is the most common site. Here in this article, we downloaded the gene expression data and clinical information from online dataset.
Neuroendocrine prostate cancer (NEPC), a highly aggressive variant of castration-resistant prostate cancer (CRPC), often emerges upon treatment with androgen pathway inhibitors, via neuroendocrine differentiation.
The therapeutic role of pelvic lymph node dissection (PLND) in prostate cancer (PCa) is unknown due to absence of randomized trials. to present a critical review on the therapeutic benefits of PLND in high risk localized PCa patients.
Metastasis has been considered as the terminal step of tumor progression. However, recent genomic studies suggest that many metastases are initiated by further spread of other metastases. Nevertheless, the corresponding pre-clinical models are lacking, and underlying mechanisms are elusive.
(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. Each of these treatment approaches has utilized an immunotherapy backbone with immune checkpoint inhibition. In a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting, Dr. Samra Turajlic discussed the source of […]
(UroToday.com) The European International Kidney Cancer Symposium 2021 virtual meeting included a basic science session and a presentation by Dr. Barbara Seliger discussing the role of the tumor microenvironment in renal cancer. Dr. Seliger suggests that the hallmarks of renal cell carcinoma are sustained angiogenesis and evading immune surveillance. There are several immune escape strategies of renal […]
(UroToday.com) As part of the new directions in the management of systemic therapy session at the European International Kidney Cancer Symposium 2021 virtual meeting, Dr. Lisa DeRosa discussed the impact and manipulations of microbiomes as it pertains to renal cell carcinoma. Dr. DeRosa notes that there are 39-44 trillion microbes, which translates to 1.3-2.2 bacteria to every […]
(UroToday.com) The European International Kidney Cancer Symposium 2021 virtual meeting’s keynote lecture was provided by Dr. David McDermott discussing kidney cancer as a model for a curable neoplasm.
